Quantcast

ChromaDex Chief Scientific Advisor Dr. Charles Brenner Receives 2020 National Scientific Achievement Award from the American Society for Nutrition

Dr. Charles Brenner’s latest research focuses on effect of SARS-CoV-2 infection on cells’ NAD levels

LOS ANGELES–(BUSINESS WIRE)–$CDXC #CellularHealth–ChromaDex Corp. (NASDAQ:CDXC) today announced Dr. Charles Brenner, the Roy J. Carver Chair and Head of Biochemistry at the University of Iowa and ChromaDex Chief Scientific Advisor, was named the 2020 recipient of the Mary Swartz Rose Senior Investigator Award from the American Society for Nutrition (ASN) and its Foundation. This award, presented by ASN and supported by the Council for Responsible Nutrition (CRN), recognizes an investigator who has contributed outstanding research in the field of bioactive compounds for human health.

Dr. Brenner is one of the world’s foremost experts in nicotinamide adenine dinucleotide (NAD) research. In 2004, Dr. Brenner discovered the vitamin activity of nicotinamide riboside (NR), an important NAD precursor (or booster) through a gene pathway that is activated when cells are under multiple forms of metabolic stress. NR is also known as Niagen®, a form of vitamin B3 exclusively licensed by ChromaDex.

In the past two decades, Dr. Brenner has made multiple groundbreaking contributions to NAD metabolism, which include discovery of genes, enzymes, NAD biosynthetic intermediates and NAD regulatory systems, solving the crystal structure of human NMRK1, developing the methods for quantitative NAD metabolomics, and demonstrating the activity of oral NR in animal models of fatty liver disease, obesity, type 2 diabetes, diabetic and chemotherapeutic neuropathy, heart failure, central brain injury, postpartum and neurodevelopment. Dr. Brenner also led the first clinical trial of NR, which established safe oral availability in humans and has contributed to three additional published human randomized placebo-controlled trials of Niagen®.

Most recently, Dr. Brenner and his colleagues released promising preclinical results showing that coronavirus infection depletes cellular NAD and infected cells activate the NAD defense pathway that utilizes nicotinamide riboside (NR) as part of their innate immune response.

“We are proud to see recognition of Dr. Brenner’s great work in the science of NAD by ASN and CRN,” says ChromaDex CEO Rob Fried. “We look forward to our continued research collaboration with Dr. Brenner on the importance of nicotinamide riboside (Niagen) in the body’s response to a broad range of physiologic stressors including immune stress.”

The ASN and CRN will present Dr. Brenner as a featured speaker as part of Nutrition 2020 Live Online being held June 1 – 4, 2020. Interested members of the public can register for this free virtual event at meeting.nutrition.org.

For additional information on ChromaDex, please visit www.chromadex.com.

About ChromaDex:

ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of NAD and its impact on human health. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to the demonstrated oral activity of NR, its importance in the body’s response to a broad range of physiologic stressors including immune stress, and whether the data from the preclinical research showed coronavirus infection depletes cellular NAD and infected cells activate the NAD defense pathway that utilizes NR as part of their innate immune response. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects”, “anticipates”, “intends”, “estimates”, “plans”, “potential”, “possible”, “probable”, “believes”, “seeks”, “may”, “will”, “should”, “could” or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 as amended, ChromaDex’s Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

 

Contacts

ChromaDex Media Contact:
Alex Worsham, Senior Director of Global Corporate Communications

310-388-6706 ext. 689

[email protected]

ChromaDex Investor Relations Contact:
Brianna Gerber, Vice President of FP&A and Investor Relations

949-419-0288 ext. 127

[email protected]

ChromaDex Chief Scientific Advisor Dr. Charles Brenner Receives 2020 National Scientific Achievement Award from the American Society for Nutrition

Dr. Charles Brenner’s latest research focuses on effect of SARS-CoV-2 infection on cells’ NAD levels

LOS ANGELES–(BUSINESS WIRE)–$CDXC #CellularHealth–ChromaDex Corp. (NASDAQ:CDXC) today announced Dr. Charles Brenner, the Roy J. Carver Chair and Head of Biochemistry at the University of Iowa and ChromaDex Chief Scientific Advisor, was named the 2020 recipient of the Mary Swartz Rose Senior Investigator Award from the American Society for Nutrition (ASN) and its Foundation. This award, presented by ASN and supported by the Council for Responsible Nutrition (CRN), recognizes an investigator who has contributed outstanding research in the field of bioactive compounds for human health.

Dr. Brenner is one of the world’s foremost experts in nicotinamide adenine dinucleotide (NAD) research. In 2004, Dr. Brenner discovered the vitamin activity of nicotinamide riboside (NR), an important NAD precursor (or booster) through a gene pathway that is activated when cells are under multiple forms of metabolic stress. NR is also known as Niagen®, a form of vitamin B3 exclusively licensed by ChromaDex.

In the past two decades, Dr. Brenner has made multiple groundbreaking contributions to NAD metabolism, which include discovery of genes, enzymes, NAD biosynthetic intermediates and NAD regulatory systems, solving the crystal structure of human NMRK1, developing the methods for quantitative NAD metabolomics, and demonstrating the activity of oral NR in animal models of fatty liver disease, obesity, type 2 diabetes, diabetic and chemotherapeutic neuropathy, heart failure, central brain injury, postpartum and neurodevelopment. Dr. Brenner also led the first clinical trial of NR, which established safe oral availability in humans and has contributed to three additional published human randomized placebo-controlled trials of Niagen®.

Most recently, Dr. Brenner and his colleagues released promising preclinical results showing that coronavirus infection depletes cellular NAD and infected cells activate the NAD defense pathway that utilizes nicotinamide riboside (NR) as part of their innate immune response.

“We are proud to see recognition of Dr. Brenner’s great work in the science of NAD by ASN and CRN,” says ChromaDex CEO Rob Fried. “We look forward to our continued research collaboration with Dr. Brenner on the importance of nicotinamide riboside (Niagen) in the body’s response to a broad range of physiologic stressors including immune stress.”

The ASN and CRN will present Dr. Brenner as a featured speaker as part of Nutrition 2020 Live Online being held June 1 – 4, 2020. Interested members of the public can register for this free virtual event at meeting.nutrition.org.

For additional information on ChromaDex, please visit www.chromadex.com.

About ChromaDex:

ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of NAD and its impact on human health. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to the demonstrated oral activity of NR, its importance in the body’s response to a broad range of physiologic stressors including immune stress, and whether the data from the preclinical research showed coronavirus infection depletes cellular NAD and infected cells activate the NAD defense pathway that utilizes NR as part of their innate immune response. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects”, “anticipates”, “intends”, “estimates”, “plans”, “potential”, “possible”, “probable”, “believes”, “seeks”, “may”, “will”, “should”, “could” or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 as amended, ChromaDex’s Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

 

Contacts

ChromaDex Media Contact:
Alex Worsham, Senior Director of Global Corporate Communications

310-388-6706 ext. 689

[email protected]

ChromaDex Investor Relations Contact:
Brianna Gerber, Vice President of FP&A and Investor Relations

949-419-0288 ext. 127

[email protected]

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.